MPManisha Prajapat

Manisha Prajapat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manisha Prajapat has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A novel modulator of the Axin/β-Catenin interaction to restore EAAT2 expression in alzheimer’s disease: an in-silico and in-vitro approach

    by Harminder Kaur, Biman Saikia, Gajendra Choudhary, Manisha Prajapat, Ketaki Ghosh, Subrata Ghosh, Prasenjit Mondal, Ajay Prakash, Bikash Medhi

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by synaptic dysfunction and neuronal loss, with glutamate excitotoxicity playing a central role in its pathology. The astrocytic glutamate transporter EAAT2, responsible for maintaining synaptic glutamate homeostasis, is significantly downregulated in AD. Restoration of EAAT2 expression presents a promising therapeutic strategy. This study explores the potential of modulating the Wnt/β-catenin signaling pathway to enhance EAAT2 levels by targeting the Axin-1/β-catenin interaction. Through virtual screening of 120,993 compounds from the Asinex-CNS database, five lead candidates were identified based on molecular docking, MMGBSA scores, and drug-likeness parameters. Advanced in-silico analyses—including Principal Component Analysis, Dynamic Cross-Correlation Mapping, molecular dynamics simulations, and MM/PBSA binding free energy calculations—highlighted BAS 04937103 as the most promising compound for disrupting β-catenin degradation. In vitro validation using C6 glioma cells and primary astrocytic cultures demonstrated that BAS 04937103 enhanced β-catenin stabilization and nuclear translocation, reduced Axin-1 expression, and significantly upregulated EAAT2 levels. These molecular effects corresponded with decreased extracellular glutamate concentrations, improved glutamate uptake, and reduced oxidative stress. Collectively, these findings establish BAS 04937103 as a novel modulator of the Axin/β-catenin interaction with therapeutic potential in mitigating glutamate-mediated neurotoxicity in Alzheimer’s disease.


  • Neuroprotective effect of the standardised extract of Bacopa monnieri (BacoMind) in valproic acid model of autism spectrum disorder in rats

    by Mishra Abhishek, Singla Rubal, Kumar Rohit, Joshi Rupa, Sarma Phulen, Kaur Gurjeet, Sharma Amit Raj, Prajapat Manisha, Bhatia Alka, Pallola Ramprasad, et al.


  • Identification of novel anti‐Alzheimer’s drugs through inhibition of LRP‐DKK interaction: A computational approach using high throughput virtual screening and molecular dynamics studies

    by Manisha Prajapat

    Background: Activation of WNT signalling pathway was involved in a neuroprotective mechanism against amyloid beta toxicity (1). Inhibition of this pathway is associated with GSK‐3 beta activation, tau hyperphosphorylation, neuronal apoptosis (1), (2) and is implicated in Alzheimer’s disease (1). DKK‐1 competes with Wnt for the binding to LRP5/6 receptor (3) and disrupts the Wnt‐induced Fzd‐Wnt‐LRP6 complex (4) and thus antagonizes the neuro‐protective effect of WNT. In this study, we have targeted the DKK‐LRP interaction through virtual screening the first time to develop novel anti‐Alzheimer’s agent.Method: Based upon crystal structure information and protein validation using Ramachandran Plots, a crystal structure (PDB: 3S8V) was selected for further works. In this study, we have targeted the surface of LRP 5/6, which is interacting with DKK and grid was generated on LRP. The virtual screening of Asinex database library (N=19642) was done against this grid. Molecules were selected on the basis of good dock score and binding free energy calculation using MMGBSA in Schrodinger GLIDE (5)(6). The protein ligand complex structure stability were also evaluated by molecular dynamic simulation study (7). ADMET profile of the screened ligands were evaluated using Quick prop module of Schrodinger.Result: After running the virtual screening protocol (HTVS: SP: XP), 14 compounds were screened out, which showed significant binding top the DKK1 binding interface of LRP. These compounds were further evaluated on basis of docking score and MMGBSA. On the basis of After then on the basis of ADME profile selected 2 compound id ZINC000100138828 and ZINC000247940500 for further molecular dynamic simulation study which were shown the compound ZINC000100138828 had an avg. RMSD of ∼4.0Å, also the RMSF is 2.4 Å for overall protein side chain residue was reduced with reference to the apo form. It is displays rich interaction profile and strength with core binding residues (A: Pro833, B: Tyr706, B: Glu708, B: Arg751 and B: Ile681).Conclusion: ZINC000100138828 is a potent binder to the DKK1 binding surface on LRP5/6. It needs further in‐vitro and preclinical validation as a potential anti‐Alzheimer’s agent.


  • Yogic Neti-Kriya Using Povidone Iodine: Can it have a Preventive Role Against SARS-CoV-2 Infection Gateway?

    by Phulen Sarma, Anusuya Bhattacharyya, Ajay Prakash, Hardeep Kaur, Manisha Prajapat, Mukundam Borah, Subodh Kumar, Seema Bansal, Saurabh Sharma, Gurjeet Kaur, et al.

    During this COVID-19 pandemic, except steroid, none of the therapeutic measures have showed any evidence of efficacy. Traditionally jala-neti using lukewarm salted water remains a yogic way of maintaining upper airway hygiene. Saline irrigation decreases the concentration of inflammatory mediators (e.g. histamine, leukotriene etc.) in nasal secretions, reduces the severity and frequency of sinusitis, reduce need of antibiotic therapy and restores competency of nasal mucosa. Jala-neti is an integral part of six cleansing techniques of yogic kriyas practised in India since thousands of years. Jala-neti can clean the upper airways, prevents colonization of infectious agents, removes foreign bodies, prevents stasis of mucous and subsequently enhances the drainage of paranasal sinuses and maintain health. Regular practice of Jala neti improves nasal symptoms and overall health status of patients with sinusitis. Jala-neti sample can even be used for COVID-19 diagnosis. Povidone iodine (PVP-I) has been utilized as a time tested antimicrobial agent with broad spectrum coverage against wide range of bacteria and viruses. Anti-SARS-CoV-2 action of PVP-I was seen at a concentration as low as 0.45%. PVP-I is generally well tolerated upto 5%, however nasal ciliotoxicity is reported at this concentration, however, this toxicity is not reported with lower concentrations(1.25% and 0.5%). So, theoretically, by using neti-kriya with povidone iodine (0.5–1%) as irrigation solution can combine and enhance the protection against COVID-19 and this can be an important armor in the fight against COVID-19. However, this hypothesis needs to be validated in real life clinical trial scenario before implementing.


  • Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review

    by Subodh Kumar, Phulen Sarma, Hardeep Kaur, Manisha Prajapat, Anusuya Bhattacharyya, Pramod Avti, Nishant Sehkhar, Harpinder Kaur, Seema Bansal, Saniya Mahendiratta, et al.


  • Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2

    by Manisha Prajapat, Nishant Shekhar, Phulen Sarma, Pramod Avti, Sanjay Singh, Hardeep Kaur, Anusuya Bhattacharyya, Subodh Kumar, Saurabh Sharma, Ajay Prakash, et al.


  • Premature graying of hair: Risk factors, co‐morbid conditions, pharmacotherapy and reversal—A systematic review and meta‐analysis

    by Saniya Mahendiratta, Phulen Sarma, Hardeep Kaur, Sukhmandeep Kaur, Harpinder Kaur, Seema Bansal, Davinder Prasad, Manisha Prajapat, Sujata Upadhay, Subodh Kumar, et al.

    Premature graying of hair (PGH) being a very common entity for which pharmacotherapy and reversibility are not properly addressed. Therefore, this systematic review was conducted to address these issues. For this relevant study were selected from various databases including PubMed, EMBASE, OVID, Web of science, Scopus and Google Scholar till January 20, 2019. Studies which reported risk factors, co‐morbid conditions associated with PGH, its pharmacotherapy and reversal were included in the study. Although many risk factors are reported in literature, smoking, vitamin deficiency (B12, folic acid and B7), mineral deficiency (low serum calcium and serum ferritin) are found to be associated with PGH. Other important risk factors are family history of PGH, obesity, high B.P, lack of exercise, drugs, genetic syndromes, dyslipidemia, thyroid disorders, hyperuricemia and alteration in liver function. PGH is found to be an important marker of CAD, more so in case of smoker. Among different pharmacotherapeutic management options, low grade recommendation (2A) is given to calcium pantothenate, PABA, calcium pantothenate + PABA combination. Anu‐tailam is the only herbal agent evaluated in clinical research settings. Finally treating the accompanying pathologies led to the reversal of the disease in many cases.


  • Therapeutic options for management of Hori's nevus: A systematic review

    by Harpinder Kaur, Phulen Sarma, Sukhmandeep Kaur, Hardeep Kaur, Manisha Prajapat, Saniya Mahendiratta, Subodh Kumar, Prasad Thota, Davinder Parsad, Bikash Medhi

    Introduction Hori's nevus is a pigmentation disorder reported mainly in middle‐aged Asian women. There is no systematic review addressing its pharmacotherapy. Materials and methods The population for our systematic review was patients with a clinical/ histological diagnosis of Hori's nevus (both sex, any age group). We screened 5 literature databases using relevant keywords. All RCTs, observational studies and case series mentioning at least one intervention and outcome of that intervention were included. Result 19 studies were included in the final systematic review from total 680 identified non‐duplicate records. Different forms of laser[alexandrite laser (QSAL and PSAL), Nd:YAG laser (QSNYL high fluence, low fluence, 532 followed by 1064 nm), Er: YAG and Nd:YAG combination, ruby laser (QSRL), CO2 laser followed by QSRL] and dermabrasion were found to be useful in treatment of Hori' nevus. Conclusion Among alexandrite lasers, PSAL is more efficacious and safe than QSAL.In case of high fluence QSNYL, hyperpigmentation rate is quite high while low fluence QSNYLrequires morenumber of treatment sessions. The combined 1064nm + 532 nm protocol is better in terms of efficacy and safety. Er:YAG + Nd:YAG combination have similar efficacy and added advantage of synergistic action and no adverse event.